Becton, Dickinson and Co (BDX) has disclosed a new risk, in the Corporate Activity and Growth category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Becton, Dickinson and Co. faces significant risks in realizing the anticipated benefits from the merger of its Biosciences and Diagnostic Solutions business with Waters. The transaction may not deliver the expected operational, financial, and strategic advantages, potentially leading to increased expenses and diverted resources due to transition service commitments. Additionally, the transaction’s tax-free status for U.S. federal income tax purposes is uncertain, posing a risk of substantial tax liabilities. These factors could negatively impact the company’s business, financial condition, and operational results.
Overall, Wall Street has a Moderate Buy consensus rating on BDX stock based on 2 Buys and 5 Holds.
To learn more about Becton, Dickinson and Co’s risk factors, click here.